Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

However, in multivariable analysis, despite a clear trend, ultimately receipt of a prior BCMA-DT was not independently associated with ORR or PFS ( p = 0.057 and p = 0.1, respectively).

also in 19,460 other papers

However, in multivariable analysis, while there was a strong trend toward worse outcomes for patients with prior BCMA-DT exposure—particularly ORR ( p = 0.057 for ORR; p = 0.1 for PFS)—receipt of prior BCMA-DT was not independently associated with inferior ORR or PFS, as these differences did not reach statistical significance.

also in 5,725 other papers

While patients receiving teclistamab within 6 months of their last BCMA-DT exposure had a numerically lower ORR (42% versus 51.5%; p = 0.38) and CR or better rate (15% versus 25%; p = 0.19) compared to patients receiving teclistamab ≥6 months after their last BCMA-DT exposure, this did not reach statistical significance.

also in 111,027 other papers